Brief: Aim Vaccine Says Phase 3 Clinical Trials For 13-Valent Pneumonia Conjugate Vaccine Completed
04/03/2024 24:29
March 4 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* PHASE III CLINICAL TRIALS FOR 13-VALENT PNEUMONIA
CONJUGATE
VACCINE, HAS BEEN COMPLETED
* PHASE III CLINICAL TRIALS FOR ITERATIVE SERUM-FREE RABIES
VACCINE AND 23-VALENT PNEUMONIA POLYSACCHARIDE VACCINE COMPLETED
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine